Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
D'Arcy
Christopher A
CA
Willkens
Robert F
RF
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000145:classification / Q000628:therapy*; D001691:Biological Therapy; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D012219:Rheumatology / Q000379:methods*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D000069285:Infliximab; D008727:Methotrexate